# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.

Date prepared August 20, 2012

2. Sponsor information Tyson Bioresearch, Inc. 5 F., # 22, Ke E. Road III., science based industrial park Chun-Nan, Miao-Li county, Taiwan 350

Correspondent:   
WEN-HAI TSAI   
Phone: 886-37-585988 EXT 720   
Facsimile: 886-37-585996

Device name and classification

Device Name: TysonBio MD100 Blood Glucose Monitoring System TysonBio MD100 Pro Blood Glucose Monitoring System TysonBio MD100 Control Solution TysonBio MD100 Test Strip TysonBio MD100 Pro Test Strip

Common Names: Blood Glucose Monitoring System

Classification

Classification Regulation: 21 CFR 862.1345 and 21CFR 862.1660   
Classification: Class I (Glucose Test System) Class I (Quality control material )   
Product Code: LFR (Glucose Dehydrogenase, Glucose) NBW (System, Test, Blood Glucose, Over The Counter) JJX, Single (specified) analyte controls (assayed and unassayed)   
Panel - Clinical Chemistry and Toxicology

# Device description

The TysonBio MD100 Blood Glucose Monitoring System consists of three main products: the meter, test strip, and control solutions. These products have been designed, tested, and proven to work together as a system accurate blood glucose test results. Use only TysonBio MD100 Test Strips and TysonBio MD100 Control Solution with the TysonBio MD100 Blood Glucose. Monitoring System.

The TysonBio MD100 Pro Blood Glucose Monitoring System consists of three main products: the meter, test strip, and control solutions. These products have been designed, tested, and proven to work together as a system accurate blood glucose test results. Use only TysonBio MD100 Pro Test Strips and TysonBio MD100 Control Solution with the TysonBio MD100 Pro. Blood Glucose Monitoring System.

The TysonBio MD100 / MD100 Pro Blood Glucose Monitoring System consists of:

a. TysonBio MD100/MD100 Pro Blood Glucose Meter b. TysonBio MD100/MD100 Pro Test Strips C. TysonBio MD100 Controi Solution

# 5. Intended use

# TysonBio MD100 Blood Glucose Monitoring System :

The TysonBio MD100 Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in capillary whole blood samples. Capillary samples may be drawn from the fingertip, palm and forearm. The TysonBio MD100 Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.

The TysonBio MD100 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The TysonBio MD100 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The TysonBio MD100 Test Strips are for use with the TysonBio MD100 Blood Glucose Meter to quantitatively measure glucose in venous whole blood sample and fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

The TysonBio MD100 Control Solutions is for use on the TysonBio MD100 Blood Glucose Monitoring Systems to check that the meter and test strips are working together properly and providing accurate results.

# TysonBio MD100 Pro Blood Glucose Monitoring System :

The TysonBio MD100 Pro Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in capillary and venous whole blood samples. Capillary samples may be drawn from the fingertip. palm and forearm. The TysonBio MD100 Pro Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control program. This system should only be used with auto-disabling, single-use lancing devices. The TysonBio MD100 Pro Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The TysonBio MD100 Pro Blood Glucose Test Strips are for use with the TysonBio MD100 Pro Blood Glucose Meter to quantitatively measure glucose in venous whole blood sample and fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

The TysonBio MD100 Control Solutions is for use on the TysonBio MD100 Pro Blood Glucose Monitoring Systems to check that the meter and test strips are working together properly and providing accurate results.

# Test principle

The test principle is based on electrochemical biosensor technology using glucose dehydrogenase. There has been no change to the fundamental scientific technology.

# 7.Predicate device

Ascensia CONTOUR Blood Glucose Monitoring System (K062058)   

<table><tr><td rowspan=2 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate Device (K062058)</td><td rowspan=1 colspan=1>Proposed Device</td></tr><tr><td rowspan=1 colspan=1>Ascensia ContourBlood Glucose Monitoring System</td><td rowspan=1 colspan=1>TysonBio MD100 /MD100 ProBlood Glucose Monitoring System</td></tr><tr><td rowspan=1 colspan=1>Meter size</td><td rowspan=1 colspan=1>77 mm (H) x 57mm (W) x 19mm (T)</td><td rowspan=1 colspan=1>94 mm (H).xÂ·63 mm (W) x 25mm (T)</td></tr><tr><td rowspan=1 colspan=1>Meter weight</td><td rowspan=1 colspan=1>47.5 grams</td><td rowspan=1 colspan=1>60 grams without battery</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>0.6uL</td><td rowspan=1 colspan=1>0.5uL</td></tr><tr><td rowspan=1 colspan=1>AST</td><td rowspan=1 colspan=1>Palm, forearm and heel (neonates)</td><td rowspan=1 colspan=1>Palm and forearm</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>10-600mg/dL</td><td rowspan=1 colspan=1>20-600mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hematocrit range</td><td rowspan=1 colspan=1>0 ~70 %</td><td rowspan=1 colspan=1>10-70%</td></tr><tr><td rowspan=1 colspan=1>OperatingTemperatureRange:</td><td rowspan=1 colspan=1>5 to 45  (41-113F)</td><td rowspan=1 colspan=1>10 to 40  (50-104F)</td></tr><tr><td rowspan=1 colspan=1>Humidity</td><td rowspan=1 colspan=1>10-93%</td><td rowspan=1 colspan=1>10-90%</td></tr><tr><td rowspan=1 colspan=1>Memory Feature</td><td rowspan=1 colspan=1>Stores most recent 480 test results</td><td rowspan=1 colspan=1>Stores most recent 500 test results</td></tr><tr><td rowspan=1 colspan=1>Battery Type:</td><td rowspan=1 colspan=1>Two 3-volt lithium batteries(DL2032 or CR2032)</td><td rowspan=1 colspan=1>Two AAA batteries</td></tr><tr><td rowspan=1 colspan=1>Battery Life:</td><td rowspan=1 colspan=1>Approximately 1000 tests(1 yr. average use)</td><td rowspan=1 colspan=1>Approximately 1000 tests</td></tr><tr><td rowspan=1 colspan=1>Marker</td><td rowspan=1 colspan=1>Meal and log book</td><td rowspan=1 colspan=1>Meal</td></tr><tr><td rowspan=1 colspan=1>Reminder alarm</td><td rowspan=1 colspan=1>Post-Meal Test Alarm</td><td rowspan=1 colspan=1>4 user setting alarms</td></tr><tr><td rowspan=1 colspan=1>Button</td><td rowspan=1 colspan=1>Three operating button(M, up and down)</td><td rowspan=1 colspan=1>Three operating button(M, up and down)One ejection button</td></tr></table>

# Similarities:

<table><tr><td rowspan=2 colspan=1>Item</td><td rowspan=1 colspan=1>Predicate Device (K062058)</td><td rowspan=1 colspan=1>Proposed Device</td></tr><tr><td rowspan=1 colspan=1>Ascensia ContourBlood Glucose Monitoring System</td><td rowspan=1 colspan=1>TysonBio MD100 / MD100 ProBlood Glucose Monitoring System</td></tr><tr><td rowspan=1 colspan=1>Test principle</td><td rowspan=1 colspan=1>Electrochemical biosensor withglucose dehydrogenase (FAD)</td><td rowspan=1 colspan=1>Electrochemical biosensor with glucosedehydrogenase (FAD)</td></tr><tr><td rowspan=1 colspan=1>Test Sample</td><td rowspan=1 colspan=1>Whole blood(Capillary and venous blood)</td><td rowspan=1 colspan=1>Whole blood(Capillary and venous blood)</td></tr><tr><td rowspan=1 colspan=1>MeasuringTime</td><td rowspan=1 colspan=1>5 seconds</td><td rowspan=1 colspan=1>5 seconds</td></tr><tr><td rowspan=1 colspan=1>Coding</td><td rowspan=1 colspan=1>Auto coding by inserting the test strip</td><td rowspan=1 colspan=1>Auto coding by inserting the test strip</td></tr><tr><td rowspan=1 colspan=1>Hypoglycemicandhyperglycemicalarm</td><td rowspan=1 colspan=1>2 user setting alarms</td><td rowspan=1 colspan=1>2 user setting alarms</td></tr><tr><td rowspan=1 colspan=1>Average result</td><td rowspan=1 colspan=1>7,14 and 30days</td><td rowspan=1 colspan=1>7,14 and 30days</td></tr></table>

# 8.Performance characteristic summary

The performance of TysonBio MD100 / TysonBio.MD100 Pro Blood Glucose Monitoring System was studied in the laboratory and in clinical settings by healthcare professionals and lay users. The studies demonstrated that the performance of this system meets its intended use.

# . Conclusion

The TysonBio MD100 / MD100 Pro Blood Glucose Monitoring System is substantially equivalent to the predicate device.

Tyson Bioresearch, Inc.   
c/o Wen-Hai Tsai   
5 F., #22, Ke E. Road III, Science-Based Industrial Park Chu-Nan, Miao-Li County   
China (Taiwan) 350

Re: k112916 Trade Name: TysonBio MD100 Blood Glucose Monitoring System TysonBio MD100 Pro Blood Glucose Monitoring System Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 4 5$ E Regulation Name: Glucose Test System Regulatory Class: Class II Product Codes: NBW, LFR, JJX Dated: August 9, 2012 Received: August 13, 2012

Dear Wen-Hai Tsai:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/4efde6c448077bb7514ad17e7c5b5f4b91f17933f604bd82ca4e00bad8bbadae.jpg)

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known): k112916

Device Name: TysonBio MD100 Pro Blood Glucose Monitoring System

Indication for Use:

The TysonBio MD100 Pro Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in capillary and venous whole blood samples. Capillary samples may be drawn from the fingertip, palm and forearm. The TysonBio MD100 Pro Blood Glucose Monitoring System is intended for testing outside the body (in vitro diagnostic use) and is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control program. This system should only be used with auto-disabling, single-use lancing devices. The TysonBio MD100 Pro Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The TysonBio MD100 Pro Blood Glucose Test Strips are for use with the TysonBio MD100 Pro Blood Glucose Meter to quantitatively measure glucose.in venous whole blood sample and fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

The TysonBio MD100 Control Solutions is for use on the TysonBio MD100 Pro Blood Glucose Monitoring Systems to check that the meter and test strips are working together properly and providing accurate results.

Prescription Use X (21 CFR Part 801 Subpart D)

And/Or Over the Counter Use X (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/25f4ebf713c2885a6a91a4ebc4e6d77dea2a4d73a79469e43a6540ebde9feaac.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K11 210

# Indication for Use

510(k) Number (if known): k112916

Device Name: TysonBio MD100 Blood Glucose Monitoring System

Indication for Use:

The TysonBio MD100 Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in capillary and venous whole blood samples. Capillary samples may be drawn from the fingertip, palm and forearm. The TysonBio MD100 Blood. Glucose Monitoring System is intended to be used by a single person and should not be shared.

The TysonBio MD100 Blood Glucose Monitoring System is intended for self testing outside the body (in vitro diagnostic use) by.people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The TysonBio MD100 Blood Glucose Monitoring System should not be used for the diagnosis of or screening of diabetes or for neonatal use. Alternative site testing should be done only during steady - state times (when glucose is not changing rapidly).

The TysonBio MD100 Test Strips are for use with the TysonBio MD100 Blood Glucose Meter to quantitatively measure glucose in venous whole blood sample and fresh capillary whole blood samples drawn from the fingertips, forearm or palm.

The TysonBio MD100 Control Solutions is for use on the TysonBio MD100 Blood Glucose Monitoring Systems to check that the meter and test strips are working together properly and providing accurate results.

Prescription Use And/Or Over the Counter Use X (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/63a883f2507748f9877c15543de7f769e3d187264d9042759445469bd4412ca4.jpg)

Division SigneOff   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K1129160

Page 2of2